Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 11 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

18%

2 trials in Phase 3/4

Results Transparency

44%

4 of 9 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 2

4(57.1%)

Phase 3

2(28.6%)

Phase 1

1(14.3%)

7Total

Phase 2(4)

Phase 3(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials

NCT04235816Phase 3Active Not Recruiting

Improving Care Through Azithromycin Research for Infants in Africa

Role: collaborator

NCT05085340Completed

MULTIple Doses of IPTi Proposal: a Lifesaving High Yield Intervention

Role: collaborator

NCT03929757Phase 2Completed

A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants

Role: collaborator

NCT05284097Phase 2Completed

Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study

Role: collaborator

NCT04711356Phase 2Completed

Ad26.ZEBOV Booster in Children Previously Vaccinated With Ad26.ZEBOV and MVA-BN-Filo (EBOVAC Booster Study)

Role: collaborator

NCT03820739Completed

EBOVAC-Salone Extension

Role: collaborator

NCT02509494Phase 3Completed

Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo

Role: collaborator

NCT04912284Completed

Africa COVID-19 Vaccine Hesitancy

Role: collaborator

NCT03828630Completed

Lung Ultrasound to Detect Pulmonary Complications in Critically Ill Parturients

Role: collaborator

NCT02378753Phase 2Completed

STRIVE (Sierra Leone Trial to Introduce a Vaccine Against Ebola)

Role: collaborator

NCT02380625Phase 1Unknown

Multiple Treatments for Ebola Virus Disease (EVD)

Role: collaborator

All 11 trials loaded